Study participants. Values are n (%) or median (range) unless otherwise specified.
| Characteristics | n |
|---|---|
| n | 33 |
| Male:female | 8:25 |
| JIA category | |
| Oligoarticular | 7 (21) |
| RF− polyarticular | 11 (33) |
| RF+ polyarticular | 1 (3.0) |
| Psoriatic | 6 (18) |
| ERA | 8 (24) |
| No. previous rounds of IA CS injections | |
| 1 | 7 (21) |
| 2 | 18 (54) |
| 3 | 8 (24) |
| Age at first IA IFX injection, yrs | 12 (2.9–18) |
| No. bilateral IFX injections | |
| 1 | 5 (15) |
| 2 | 16 (48) |
| 3 | 7 (21) |
| 4 | 2 (6.1) |
| 5 | 1 (3.0) |
| 6 | 1 (3.0) |
| 7 | 1 (3.0) |
| Interval between first and last injection, mos | 2 (0–12) |
| Interval between first and last MRI, mos | 9 (2–27) |
| Systemic medicines prior to first IA IFX dose | |
| None | 1 (3.0) |
| MTX alone | 2 (6.1) |
| TNFi alone | 5 (15) |
| TNFi + DMARD, MTX, or LEF* | 25 (76) |
| LEF + ABA* | 1 (3.0) |
↵* One subject was treated with ETN followed by ABA; the sum of patients represented in this table is 34 because this 1 subject fell into 2 separate categories. JIA: juvenile idiopathic arthritis; RF: rheumatoid factor; ERA: enthesitis-related arthritis; IA: intraarticular; CS: corticosteroid; IFX: infliximab; MRI: magnetic resonance imaging; MTX: methotrexate; TNFi: tumor necrosis factor inhibitor; DMARD: disease-modifying antirheumatic drug; LEF: leflunomide; ABA: abatacept; ETN: etanercept.